Bain Capital Life Sciences Investors, LLC

Est. AUM

$1.11B

13F long equity, this entity only

Positions

Period

Mar 2026 (Q1)

SEC EDGAR

Mar 2026 (Q1)

#	Issuer	Class	Value	Shares	% Portfolio	Discretion
1	HEARTFLOW INC	COM	$254.2M	10448158	22.93%	SOLE
2	NEWAMSTERDAM PHARMA COMPANY	ORDINARY SHARES	$233.9M	7306566	21.09%	SOLE
3	OLEMA PHARMACEUTICALS INC	COM	$111.4M	7473238	10.05%	SOLE
4	SAVARA INC	COM	$96.1M	17600621	8.67%	SOLE
5	PHARVARIS N V	COM	$75.6M	2675509	6.82%	SOLE
6	SOLID BIOSCIENCES INC	COM NEW	$70.6M	9808819	6.37%	SOLE
7	X4 PHARMACEUTICALS INC	COM NEW	$32.9M	7967454	2.97%	SOLE
8	DIANTHUS THERAPEUTICS INC	COM	$30.4M	362470	2.74%	SOLE
9	ANNEXON INC	COM	$28.9M	5212674	2.60%	SOLE
10	KYVERNA THERAPEUTICS INC	COM	$26.8M	3110000	2.42%	SOLE
11	CABALETTA BIO INC	COM	$26.0M	9677125	2.35%	SOLE
12	CENTESSA PHARMACEUTICALS	SPONSORED ADS	$25.2M	635000	2.27%	SOLE
13	ALKERMES PLC	SHS	$21.6M	610000	1.95%	SOLE
14	RAPID MICRO BIOSYSTEMS INC	CLASS A COM	$19.1M	8434560	1.73%	SOLE
15	C4 THERAPEUTICS INC	COM STK	$18.9M	7171910	1.70%	SOLE
16	ATEA PHARMACEUTICALS INC	COM	$12.7M	2360638	1.15%	SOLE
17	DISC MEDICINE INC	COM	$9.0M	141234	0.81%	SOLE
18	UPSTREAM BIO INC	COM	$7.8M	867211	0.70%	SOLE
19	XILIO THERAPEUTICS INC	COM	$5.6M	664021	0.50%	SOLE
20	NEWAMSTERDAM PHARMA COMPANY	*W EXP 99/99/999	$2.0M	99999	0.18%	SOLE

Values in USD (reported in $thousands on 13F). Source: SEC EDGAR.